Yokogawa Announces Synaptic Business Automation(TM) Concept for Industrial Automation and Control Business
Yokogawa Electric Corporation (TOKYO:6841) announces Synaptic Business Automation(TM), a new industrial automation and control business concept that expresses the company’s commitment to working with its customers to sustain their creation of corporate value. Based on the ideals expressed in the Synaptic Business Automation concept, Yokogawa will help companies achieve a transformation in how they conduct their business.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171105005001/en/
Creation of value through Synaptic Business Automation for profitable and sustainable growth (Graphic: Yokogawa Electric Corporation)
A Closer Look at Synaptic Business Automation
Manufacturers face a variety of challenges today, ranging from volatile shifts in the prices of crude oil and other raw materials and stiffening environmental and safety regulations to structural changes in their industries. To remain competitive, they must have the agility to adapt quickly to change.
To guide its efforts to assist companies in meeting such challenges, Yokogawa adheres to a vision statement that reads, “Through ‘Process Co-Innovation,’ Yokogawa creates new value with its clients for a brighter future.” We help companies improve efficiency and profitability by getting their various business units to work together more effectively and by eliminating barriers that impede the flow of information and goods throughout the supply chain and between companies.
As the Internet of Things gains traction, a digitalization of processes is underway whereby the use of big data and artificial intelligence is yielding valuable insights needed to make business decisions. The Synaptic Business Automation concept clearly expresses Yokogawa’s commitment to using the latest information technologies and its decades of experience with plant management and industrial processes, portfolio of automation solutions, and consulting expertise to help its customers transform their businesses.
The Synaptic Business Automation concept takes its name from the synapse, a structure in the nervous system that plays a role in the transfer of signals to other parts of the human body. Synaptic Business Automation expresses an ideal state for a business whereby the synthesizing of data, systems, organizations, knowledge, and supply chains adds value and strengthens competitiveness. The linked data on manufacturing processes, plant operations, human resources, and supply chains can be organized, integrated, controlled, broken down, and analyzed to yield insightful decisions at various levels in the organization, from operations in the field to corporate management.
Ways in which Synaptic Business Automation creates corporate value for our customers:
Adapt more flexibly to changes in such areas as health, safety, security and the environment (HSSE), organizational optimization, and regulatory compliance.
Optimize the total expenditure (TOTEX) components of capital expenditure (CAPEX) and operational expenditure (OPEX) over the entire lifecycle of a plant, and improve reliability. Also, directly create value by solving issues and optimizing operations throughout a supply chain, thereby enhancing productivity and profitability.
Work with specific customers to create new business models that foster manufacturing excellence by such means as supplying cloud-based services that drive collaboration with their customers and suppliers and to introduce environmentally friendly manufacturing practices that are essential for a sustainable society.
Yokogawa has many years of experience in working with operational technology (OT). By combining its in-depth knowledge of plant management, operations, industries, and processes, its portfolio of automation and other information technology solutions, and its consulting expertise, the company is uniquely positioned to create new value. Working together with its customers based on the Co-innovating tomorrow (R) corporate brand slogan, Yokogawa is committed to helping them achieve the ideals expressed in its Synaptic Business Automation concept.
For more information
Yokogawa's global network of 113 companies spans 60 countries. Founded in 1915, the US$3.5 billion company engages in cutting-edge research and innovation. Yokogawa is active in the industrial automation and control (IA), test and measurement, and aviation and other businesses segments. The IA segment plays a vital role in a wide range of industries including oil, chemicals, natural gas, power, iron and steel, pulp and paper, pharmaceuticals, and food. Targeting this segment, Yokogawa helps companies maximize their profits by offering a wide range of highly reliable products and working with the subsidiary KBC Advanced Technologies to provide premium solutions and services. For more information about Yokogawa, please visit www.yokogawa.com
The names of corporations, organizations, and products herein are either trademarks or registered trademarks of their respective holders.
Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Norsk Titanium Announces Strategic Investment from Rose Park Advisors’ Disruptive Innovation Fund20.11.2017 16:00 | Tiedote
Norsk Titanium, the metal additive manufacturing pioneer, today announced it has closed on a significant investment from Rose Park Advisors’ Disruptive Innovation Fund, known for its application of the theory of Disruptive Innovation® developed by co-founder Clayton Christensen. Terms of the investment were not released. “This strategic investment from Rose Park Advisors underscores the ability of Norsk Titanium’s Rapid Plasma Deposition™ (RPD™) technology to disrupt the metal manufacturing processes,” said Norsk Titanium Chairman of the Board John Andersen, Jr. “There are few people that are as widely respected by more business leaders than Dr. Christensen. We are humbled by his recognition of our technology and business model.” “Our strong relationships in commercial aerospace have allowed us to improve our processes and create a platform technology under the watchful eyes
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential20.11.2017 16:00 | Tiedote
Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients. “Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,“ said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compoun
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 11:43 | Tiedote
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 11:29 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 11:00 | Tiedote
(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 11:00 | Tiedote
Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme